Cluster: COVID-19

Cluster: COVID-19

A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.

All edits by  Jason D. Rowley 

Edits on 9 Sep, 2020
Jason D. Rowley
Jason D. Rowley edited on 9 Sep, 2020
Edits made to:
Article (+162/-162 characters)
Article

University of Oxford/AstraZeneca

Sinovac

Gamaleya Research Institute

Wuhan Institute of Biological Products/Sinopharm

BioNTech/Fosun Pharma/Pfizer

Moderna/NIAID

CureVac

  • University of Oxford/AstraZeneca
  • Sinovac
  • Gamaleya Research Institute
  • Wuhan Institute of Biological Products/Sinopharm
  • BioNTech/Fosun Pharma/Pfizer
  • Moderna/NIAID
  • CureVac
Edits on 27 Jul, 2020
Jason D. Rowley
Jason D. Rowley edited on 27 Jul, 2020
Edits made to:
Article (+3 rows) (+9 cells) (+174 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

CanSino Biologics

Adenovirus Type 5 vector

Phase I

Phase I and Phase II

National Institute of Allergy and Infectious Diseases (NIAID)

mRNA (mRNA-1273)

Phase I

Jason D. Rowley
Jason D. Rowley edited on 27 Jul, 2020
Edits made to:
Article (+1 rows) (+3 cells) (+39 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

GeneCure Biotechnologies

Biologic

Phase I

Jason D. Rowley
Jason D. Rowley edited on 27 Jul, 2020
Edits made to:
Article (+1 cells) (+35 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

AbCellera Biologics

Clinical trials, starting June 2020

Edits on 10 Jul, 2020
Jason D. Rowley
Jason D. Rowley edited on 10 Jul, 2020
Edits made to:
Article (+353 characters)
Article

In the United States a nation-wide, federal-level mask order is not possible due to the sovereignty of U.S. states. Accordingly, U.S. states specify their own local policies and regulations around wearing masks. Some states require that masks be worn in certain public settings (such as inside businesses) while others have enacted no such requirements.

Edits on 12 May, 2020
Jason D. Rowley
Jason D. Rowley approved a suggestion from Golden's AI on 12 May, 2020
Edits made to:
Article (+16/-16 characters)
Article

Droplet digital PCR (ddPCR) was used to test for SARS-CoV-2 viral RNA in aeorsols collected on gelatin filters in patient and medical staff areas at Renmin Hospital of Wuhan UniversityWuhan University, Wuchang Fangcang Field Hospital and public areas in Wuhan.

Edits on 22 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 22 Apr, 2020
Edits made to:
Article (+275 characters)
Article

Zoe, a health science company headquartered in London, originally started as a nutrition science company, but it launched a COVID-19 symptom tracker and online dashboard for the United Kingdom. The company says it has gathered data from over 1 million volunteer contributors.

Edits on 16 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 16 Apr, 2020
Edits made to:
Article (+40/-40 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

HaloVaxHaloVax (Joint venture between Hoth Therapeutics and Voltron TherapeuticsVoltron Therapeutics)/The Vaccine & Immunotherapy Center at the Massachusetts General Hospital

Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)

Pre-clinical; Animal study results by October 2020

Imophoron LtdImophoron Ltd/Bristol University's Max Planck Center

VLP; ADDomerTM multiepitome display

Pre-clinical

Jason D. Rowley
Jason D. Rowley edited on 16 Apr, 2020
Edits made to:
Article (-42 rows) (-109 cells) (-109 characters)
Article

Manufacturers of N95 masks

Company
Headquarters
Factory locations

3M

Maplewood, Minnesota, USA

Shanghai, China

Changhua City, Taiwan

Singapore

Markham, Ontario, Canada

Salt Lake City, Utah, USA

Kowloon, Hong Kong, China

Shenzhen, Guangdong, China

Daxi District, Taoyuan City, Taiwan

Songjiang, Shanghaim China

Songjiang, Shanghaim China

Newmarket, Ontario, Canada

Lenexa, Kansas, USA

Lübeck, Schleswig-Holstein, Germany

Beijing, China

Miaoli County, Taiwan

Gerson Co.

Middleborough, Massachusetts, USA

Middleborough, Massachusetts, USA

Shenzhen, China

Paoli, Pennsylvania, United States

Guangzhou, Guangdong, China

Guangzhou, Guangdong, China

Alpharetta, GA, USA

Hangzhou, Zhejiang, China

Charlotte, North Carolina, USA

Barranquilla, Colombia

Barranquilla, Colombia

Kilmallock, County Limerick, Ireland

Bangkok, Thailand

Saitama, Kanto, Japan

Oyama, Kanto, Japan

Jiangyin, Jiangsu, China

Jiangyin, Jiangsu, China

Minster Lovell, Oxfordshire, UK

Irving, Texas, United States

Tokyo, Japan

Saint-Barthélemy-d'Anjou, Maine-et-Loire, France

Angers, France

Page 1 of 2

Manufacturers of face masks, surgical masks, and respirators (including N95)

Jason D. Rowley
Jason D. Rowley edited on 16 Apr, 2020
Edits made to:
Article (+46/-12 characters)
Article

Other distributed computing projects include:

  • Folding@home
Jason D. Rowley
Jason D. Rowley edited on 16 Apr, 2020
Edits made to:
Article (+48/-48 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

Flow PharmaFlow Pharma

Protein subunit, peptide

Pre-clinical

GeneOne Life ScienceGeneOne Life Science/Houston MethodistHouston Methodist

RNA

Pre-clinical

Edits on 15 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 15 Apr, 2020
Edits made to:
Article (+17 rows) (+59 cells) (+2725/-14 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

AbCellera Biologics

DARPDARPAA, Eli LillyEli Lilly

Flow Pharma

Protein subunit, peptide

Pre-clinical

GeneOne Life Science/Houston Methodist

RNA

Pre-clinical

German Center for Infection Research (DZIF)

Live attenuated virus, measles virus

Pre-clinical

HaloVax (Joint venture between Hoth Therapeutics and Voltron Therapeutics)/The Vaccine & Immunotherapy Center at the Massachusetts General Hospital

Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)

Pre-clinical; Animal study results by October 2020

Protein subunit, plant produced

Pre-clinical

Imophoron Ltd/Bristol University's Max Planck Center

VLP; ADDomerTM multiepitome display

Pre-clinical

DPX-COVID-19, protein subunit, lipid-based delivery platform

Canadian Center for Vaccinology at Dalhousie University/Izaak Walton Killiam Health Center/Nova Scotia Health Authority; Canadian Immunization Research Network/University of Laval/Global Urgent and Advanced Research Development in Canada

Phase I testing to start Summer 2020

Protein subunit; COVID-19 XWG-03 truncated Spike proteins

Pre-clinical

INO-4800. DNA vaccine, molecular clamp

Coalition Epidemic Preparedness Innovations (CEPI), Twist Bioscience, David Weiner (Wistar Institute), Keith Chappell (University of Queensland), Beijing Advaccine Biotechnology Company

Clinical trials

Recombinant proteins produced in insect cells form nanoparticle constructs

Phase I clinical trials to start around July 2020

OncoGen

Protein subunit, synthetic long peptide vaccine candidate for S and M proteins

Pre-clinical

OPENCORONA: Cobra Biologics/Karolinska Institute

DNA plasmid

Funding from the European Commission (Horizon 2020 Program)

Phase 1 starting in 2020

Shenzhen Geno-Immune Medical Institute

LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes

Clinical trials (NCT04276896) starting March 2020

Shenzhen Geno-Immune Medical Institute

Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins

Clinical trials (NCT04299724) starting February 2020

St. Petersburg Scientific Research Institute of Vaccines and Serums

Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitomes)

Pre-clinical

TNX-1800, modified horsepox virus, protein from virus is expressed

Pre-clinical

Protein subunit; S protein

Phase 1 starting as early as June 2020

Protein subunit; molecular clamp stabilized Spike protein

Pre-clinical

VBI Vaccines/National Research Council of Canada

Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS spike protein

Start Phase I at end of 2020

Protein subunit, adjuvanted microsphere peptide

Government of Saskatchewan and the Canadian Federal Government

Pre-clinical; Animal testing results expected in April 2020

Page 1 of 2
Edits on 9 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 9 Apr, 2020
Edits made to:
Article (+49/-49 characters)
Article

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

RT-PCR, Fortitude Kit 2.0

Agency for Science, Technology and ResearchAgency for Science, Technology and Research (A*STAR), MiRXESMiRXES

Jason D. Rowley
Jason D. Rowley edited on 9 Apr, 2020
Edits made to:
Article (+181/-88 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

TakisTakis/Applied DNA Sciences/EvvivaxEvvivax

DNA

Pre-clinical

Translate BioTranslate Bio, Sanofi PasteurSanofi Pasteur

mRNA vaccine

University of Hong KongUniversity of Hong Kong

Live attenuated

Pre-clinical

Zydus CadilaZydus Cadila

DNA plasmid

Pre-clinical

Jason D. Rowley
Jason D. Rowley edited on 9 Apr, 2020
Edits made to:
Article (+97/-82 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

Inovio Pharmaceuticals

INO-4800. DNA vaccine, molecular clamp

Coalition Epidemic Preparedness Innovations (CEPI), Twist Bioscience, David Weiner (Wistar Institute), Keith Chappell (University of QueenslandUniversity of Queensland), Beijing Advaccine Biotechnology Company

Replicating viral vector; measles vector

Coalition Coalition for Epidemic PreparednessEpidemic Preparedness Innovations (CEPI)

Pre-clinical; Start animal testing in April 2020

VLP produced in plants

Animal testing

Gene-encoded antibody vaccine, non-viral nanoparticle delivery

Pre-clinical

Edits on 8 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Article (+29/-29 characters)
Article

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

Panther Fusion SARS-CoV-2

Hologic, Inc.Hologic, Inc.

identification of the virus causing COVID-19

U.S. FDA EUA

...
Vaporized Hydrogenhydrogen Peroxideperoxide
Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Article (+32/-19 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

Chinese Center for Disease Control and Prevention/Tongji University/SterminaUniversity/Stemirna Therapeutics

RNA; mRNA

Pre-clinical

Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Article (-2 rows) (+2/-5 cells) (+127/-178 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

Institut Pasteur/Themis/UniversityPasteur/Themis Bioscience/University of Pittsburgh

Replicating viral vector; measles vector

Coalition for Epidemic Preparedness

Pre-clinical; Start animal testing in April 2020

Kentucky BioProcessingKentucky BioProcessing (KBP)

Antigen produced in tobacco

Pre-clinical

Synthetic peptide scaffold, competitive inhibitor for ACE2 binding, trigger immune learning

Pre-clinical

VLP produced in plants

Laval University Laval University

Animal testing

VLP; plant-derived VLP

Pre-clinical

Oral vaccine, chimeric soluble protein, viral antigen delivered into mucosal tissues via self-activated endocytosis. Infectious Bronchitis Virus (IBV) vaccine developed to treat avian coronavirus has been modified to treat Covid-19.

David Zigdon, Chen Katz

Pre-clinical

RNA; mRNA

Pre-clinical

SK BiosciencesSK Biosciences

Pre-clinical; Phase 1 trials begin as soon as September 2020

Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Article (+59/-59 characters)
Article

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

Fudan University/Shanghai Jiao Tong University/RNACure BiopharmaRNACure Biopharma

RNA; LNP-encapsulated mRNA cocktail encoding VLP

Pre-clinical

GeoVaxGeoVax/BravoVaxBravoVax

Non-replicating viral vector; MVA encoded VLP

Pre-clinical

ISR Immune System RegulationISR Immune System Regulation

ISR-50

Pre-clinical; Animal study results expected in Q2 2020, Phase 1 begins Q4 2020

Edits on 7 Apr, 2020
Jason D. Rowley
Jason D. Rowley edited on 7 Apr, 2020
Edits made to:
Article (-5 rows) (-18 cells) (+173/-739 characters)
Article

COVID-19 potential treatments and interventions

Treatment / intervention
Company/Team
Stage
Other uses
Mechanism of action

Antibodies

Vir Biotechnology, Biogen, WuXi Biologics

Antibody cocktail

Regeneron, Department of Health and Human Services

Clinical trials expected summer 2020

Virus neutralizing as prophylaxis or treatment

APN01 for ARDS

Clinical trials

APN01 is a recombinant form of the protein that the SARS-CoV-2 coronavirus attacks in the lungs

Kevzara® (sarilumab, an IL-6 receptor antibody)

Regeneron, Sanofi

Clinical trials

Rheumatoid arthritis

For severe cases, may calm overactive immune response

...

COVID-19 vaccine development

Developer
Vaccine type
Team members
Stage

ExpreS2ionExpreS2ion Biotechnologies

Protein subunit; Drosophila S2 insect cell expression system VLPs

Pre-clinical

Fudan University/Shanghai Shanghai JiaoTongJiao University/RNACureTong University/RNA Cure Biopharma Biopharma

RNA; LNP-encapsulated mRNA cocktail encoding RBD

Pre-clinical

Fudan UniversityFudan University/Shanghai Shanghai JiaoTongJiao Tong University University/RNACure Biopharma

RNA; LNP-encapsulated mRNA cocktail encoding VLP

Pre-clinical

GlaxoSmithKline (GSK)

Adjuvant platform to use with vaccines to strengthen immune responses

CEPI, University of Queensland, Clover

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.